Company intelligence / Profile preview

Atalanta Therapeutics

Boston, Massachusetts, United Statesatalantatx.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Atalanta Therapeutics has developed a proprietary di-siRNA platform that enables potent, durable gene silencing throughout the brain and spinal cord. The company has demonstrated preclinical proof-of-concept for its lead programs, including sustained silencing of the huntingtin gene in animal models. IND submissions are planned for their first two programs—targeting Huntington's disease and KCNT1-related epilepsy—in late 2025. No human clinical results have been reported yet as of May 2025.[6][7]

Therapeutic areas: Neurology
Modalities: RNA interference (RNAi)Divalent small interfering RNA (di-siRNA)
Industry: Biotech

Drug pipeline

8 assets

di-siRNA SOD1

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Genentech/Roche – strategic collaboration on undisclosed CNS targets using di-siRNA technology[5][8].Biogen – previous partnership on Huntington's program; now unwinding with full rights reverting to Atalanta[8].

Beyond the preview

Go deeper on Atalanta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atalanta Therapeutics.

Explore the full profile